Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | CAR T-cell therapy in B-cell malignancies

Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the dramatic and exciting approach of using CAR T-cells to treat patients with B-cell malignancies, particularly diffuse large B-cell lymphoma. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Ansell reports on-going trials looking at other targets in Hodgkin Lymphoma, including CD30 and even the microenvironment of CD30, with a goal to work against macrophages that support growth of the malignant cell. Prof. Ansell also notes the challenges in developing treatments for T-cell lymphomas, such as targeting malignant cells and not non-malignant cells. A need for more research into ways of targeting solid tumours is also implicated.